TL;DR
This case report explores a novel bladder-preserving treatment strategy for recurrent muscle-invasive bladder cancer (MIBC) by combining maximal transurethral resection of the bladder tumor (TURBT) with chemotherapy and immunotherapy (tislelizumab). The findings suggest this approach can achieve pathological complete response and preserve bladder function, offering a promising alternative to radical cystectomy for select patients.
What Problem Does This Paper Address?
Bladder cancer, particularly muscle-invasive bladder cancer (MIBC), is a significant health concern with high recurrence and mortality rates. The current standard treatment for MIBC often involves radical cystectomy (RC) with pelvic lymph node dissection (PLND), a major surgery that can lead to significant postoperative complications and a reduced quality of life. While bladder-preserving treatments exist, such as trimodality bladder-preserving treatment (TMT), they can also have drawbacks like long-term urinary and gastrointestinal toxicities. Many patients strongly desire to preserve their bladder, highlighting the need for effective, less invasive treatment options. This paper addresses the gap in knowledge regarding the efficacy of combining maximal TURBT with chemotherapy and immunotherapy as a bladder-preserving strategy for recurrent MIBC, a scenario where standard treatments are often more aggressive.
Methods
The study presents two case reports of patients with recurrent MIBC who underwent a novel treatment regimen. The core of the methodology involved:
- Maximal Transurethral Resection of the Bladder Tumor (TURBT): This involved resecting the tumor to the depth of the superficial muscle layer, aiming for maximal tumor removal while preserving bladder tissue.
- Chemotherapy: Patients received either neoadjuvant (pre-operative) or adjuvant (post-operative) chemotherapy, with regimens including gemcitabine and cisplatin (or carboplatin for one patient due to renal insufficiency).
- Immunotherapy: Tislelizumab, a programmed death receptor-1 (PD-1) inhibitor, was administered. This is a novel humanized monoclonal antibody designed to block the PD-1 pathway, which cancer cells can exploit to evade the immune system.
- Diagnostic Tools: Standard imaging techniques like pelvic MRI and whole-abdomen enhanced CT scans were used for diagnosis, staging, and monitoring treatment response.
- Genetic Testing: In one case, next-generation sequencing (NGS) was performed on tumor tissue to analyze genetic mutations, including programmed death ligand-1 (PD-L1) expression, tumor mutation burden (TMB), and TP53 mutations.
The novelty lies in the combination of maximal TURBT with systemic chemotherapy and immunotherapy as a bladder-preserving approach for recurrent MIBC, moving beyond traditional TMT or RC.
Datasets
Not discussed in the paper. The study focuses on two individual patient cases and does not involve the use of large, standardized datasets for training or evaluation.
Key Insights and Ideas
- Bladder Preservation is Achievable: The most significant insight is that a bladder-preserving strategy combining maximal TURBT, chemotherapy, and immunotherapy can lead to pathological complete response (pCR) in recurrent MIBC, allowing patients to avoid radical cystectomy.
- Immunotherapy as a Viable Alternative: Tislelizumab, an anti-PD-1 antibody, demonstrated efficacy in these cases, suggesting its potential role in the treatment of recurrent MIBC, especially for patients who may not tolerate or are ineligible for traditional treatments like concurrent chemoradiotherapy.
- Biomarkers for Immunotherapy Efficacy: The study highlights potential predictive biomarkers for immunotherapy response. High PD-L1 expression, high tumor mutation burden (TMB), and specific TP53 mutations (in the case of the first patient) appear to be associated with a positive response to tislelizumab. This opens avenues for personalized treatment selection.
- TURBT Depth Matters: The "maximal" aspect of TURBT, resecting to the depth of the superficial muscle layer, seems crucial in achieving a significant response when combined with systemic therapies.
Key Results
- Case 1: Achieved pathological complete response (pCR) and bladder preservation after neoadjuvant chemotherapy, maximal TURBT, and subsequent tislelizumab treatment. The patient maintained a cancer-free status for 15 months with a functional bladder. Genetic analysis revealed high PD-L1 expression (CPS 70, TPS 60%), high TMB (35.89 mutations/Mb), and TP53 mutations.
- Case 2: Achieved a pathological stage downgrade to pT0 after adjuvant chemotherapy plus tislelizumab, followed by intravesical therapy. The patient maintained a cancer-free status for 8 months with a functional bladder. This patient declined genetic testing.
- Both patients experienced manageable toxic side effects from chemotherapy and immunotherapy.
Limitations and Future Work
- Small Sample Size: The most significant limitation is that this is a case report based on only two patients. The findings are preliminary and cannot be generalized to the broader MIBC population.
- Lack of Control Group: Without a control group, it's challenging to definitively attribute the outcomes solely to the combined treatment, although the pCR and bladder preservation are compelling.
- Need for Further Validation: The identified potential biomarkers (PD-L1, TMB, TP53) require validation in larger prospective studies to confirm their predictive value for tislelizumab efficacy in MIBC.
- Long-Term Outcomes: While the follow-up periods are promising (15 and 8 months), longer-term data are needed to assess the durability of the response and the sustained bladder function.
Future work should focus on prospective clinical trials to evaluate this bladder-preserving strategy in a larger cohort of MIBC patients, further investigate the role of the identified biomarkers, and establish optimal treatment protocols.
Summary updated